PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Recurrent respiratory papillomatosis

Drugs in development · updated 30 October 2026

Recurrent respiratory papillomatosis: drugs in development

Rare diseasePrevalence 1-9 / 100 000 according to Orphanet · ORPHA:60032

As of 30 October 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 5 drugs for recurrent respiratory papillomatosis. One is experimental, that is not yet approved in the United States.

3Active trials
1Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
PRGN-2012II1NCT07756840

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
Zopapogene imadenovec-drbaPapzimeos®III1NCT07901738
Bevacizumabavastin, MVASIII1NCT07756840
LenvatinibLenvatinib Mesilate Capsules, LevatinibII1NCT04645602
PembrolizumabKEYTRUDA, MK-3475II1NCT04645602

Sorted by most advanced phase and number of active trials.

All 5 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: C535297 “Recurrent respiratory papillomatosis”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch